S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
NASDAQ:VRAX

Virax Biolabs Group (VRAX) Stock Price, News & Analysis

$0.68
0.00 (-0.37%)
(As of 04/19/2024 08:51 PM ET)
Today's Range
$0.63
$0.74
50-Day Range
$0.65
$1.00
52-Week Range
$0.61
$5.45
Volume
8,200 shs
Average Volume
80,397 shs
Market Capitalization
$1.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
VRAX stock logo

About Virax Biolabs Group Stock (NASDAQ:VRAX)

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

VRAX Stock Price History

VRAX Stock News Headlines

Virax Biolabs to Participate at ESCMID Global 2024
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Virax Biolabs Group Ltd Ord
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
See More Headlines
Receive VRAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Virax Biolabs Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/21/2024
Next Earnings (Estimated)
6/12/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
N/A
Current Symbol
NASDAQ:VRAX
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Book Value
$5.73 per share

Miscellaneous

Free Float
854,000
Market Cap
$1.05 million
Optionable
Not Optionable
Beta
0.96
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. James Foster (Age 39)
    Chairman & CEO
    Comp: $347.5k
  • Mr. Jason D. Davis (Age 52)
    Chief Financial Officer
    Comp: $237.5k
  • Mr. Mark James Ternouth (Age 56)
    Chief Technical Officer & Director
    Comp: $90k
  • Dr. Tomasz Evan George (Age 40)
    Chief Scientific Officer
    Comp: $194k
  • Dr. Nigel McCracken M.Sc.
    Ph.D., Chief Operating Officer
  • Ms. Joel Yeung
    Accounting Manager
  • Mr. Clement Monteil
    Head of Scientific Research & Development
  • Mr. James Wang
    Head of Procurement & Sourcing
  • Ms. Lily Fu
    Head of Supply Chain

VRAX Stock Analysis - Frequently Asked Questions

How have VRAX shares performed in 2024?

Virax Biolabs Group's stock was trading at $1.46 at the beginning of the year. Since then, VRAX stock has decreased by 53.6% and is now trading at $0.6772.
View the best growth stocks for 2024 here
.

Are investors shorting Virax Biolabs Group?

Virax Biolabs Group saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 3,000 shares, a decrease of 80.9% from the March 15th total of 15,700 shares. Based on an average trading volume of 84,800 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.2% of the shares of the company are sold short.
View Virax Biolabs Group's Short Interest
.

When is Virax Biolabs Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024.
View our VRAX earnings forecast
.

When did Virax Biolabs Group's stock split?

Shares of Virax Biolabs Group reverse split on Monday, December 18th 2023. The 1-10 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Virax Biolabs Group IPO?

Virax Biolabs Group (VRAX) raised $7 million in an initial public offering on Thursday, July 21st 2022. The company issued 1,400,000 shares at $5.00 per share. Boustead Securities acted as the underwriter for the IPO.

How do I buy shares of Virax Biolabs Group?

Shares of VRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VRAX) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners